Symbols / AKTX Stock $5.51 -5.00% Akari Therapeutics, Plc

Healthcare • Biotechnology • United States • NCM
AKTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Abizer Gaslightwala
Exch · Country NCM · United States
Market Cap 6.31M
Enterprise Value 531.08B
Income -17.30M
Sales —
FCF (ttm) -10.22M
Book/sh 25.03
Cash/sh 5,203,000.00
Employees 5
Insider 10d —
IPO Jan 06, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E inf
Forward P/E -0.39
PEG —
P/S —
P/B 0.22
P/C —
EV/EBITDA -43,960.30
EV/Sales —
Quick Ratio 0.42
Current Ratio 0.44
Debt/Eq 2.66
LT Debt/Eq —
EPS (ttm) 0.00
EPS next Y -14.00
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-30
Earnings (prior) 2026-03-30
ROA -15.36%
ROE -68.43%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 1.14M
Shs Float 35.25B
Insider Own 24.56%
Instit Own 10.13%
Short Float 4.66%
Short Ratio 0.48
Short Interest 14.62K
52W High 59.20
vs 52W High -90.69%
52W Low 3.25
vs 52W Low 69.54%
Beta 0.54
Impl. Vol. —
Rel Volume 0.33
Avg Volume 27.96K
Volume 9.36K
Target (mean) $153.39
Tgt Median $153.39
Tgt Low $26.78
Tgt High $280.00
# Analysts 2
Recom Buy
Prev Close $5.80
Price $5.51
Change -5.00%
About

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$153.39
Mean price target
2. Current target
$5.51
Latest analyst target
3. DCF / Fair value
$-160.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.51
Low
$26.78
High
$280.00
Mean
$153.39

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-08 down Maxim Group Buy → Hold —
2026-04-01 main HC Wainwright & Co. Buy → Buy $27
2026-01-05 init Ladenburg Thalmann — → Buy $1
2025-09-09 reit HC Wainwright & Co. Buy → Buy $2
2025-07-18 init Maxim Group — → Buy $5
News
RSS: Latest AKTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-31 FARAG KAMEEL D Chief Financial Officer — 58,619 $0.75 $43,964
2025-10-22 FARAG KAMEEL D Chief Financial Officer — 6,277 $0.74 $4,645
2025-08-25 GASLIGHTWALA ABIZER Chief Executive Officer — 21,000 $0.90 $19,540
2025-06-24 GASLIGHTWALA ABIZER Chief Executive Officer — 6,146 $1.15 $7,120
2025-06-20 GASLIGHTWALA ABIZER Chief Executive Officer — 10,000 $1.20 $12,000
2025-06-17 GASLIGHTWALA ABIZER Chief Executive Officer — 15,000 $1.20 $18,000
2025-06-13 GASLIGHTWALA ABIZER Chief Executive Officer — 45,000 $1.19 $54,350
2025-06-10 GASLIGHTWALA ABIZER Chief Executive Officer — 20,000 $1.27 $25,400
2025-03-06 NEAL JAMES R Director — 4,464 $1.12 $5,000
2025-03-06 HUH HOYOUNG Director and Beneficial Owner of more than 10% of a Class of Security — 892,857 $1.12 $1,000,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
12.10
-27.34%
16.65
-0.95%
16.81
-27.21%
23.09
Research And Development
2.81
-59.69%
6.98
+28.13%
5.45
-43.00%
9.56
Selling General And Administration
9.28
-3.97%
9.66
-14.90%
11.36
-16.05%
13.53
General And Administrative Expense
9.28
-3.97%
9.66
-14.90%
11.36
-16.05%
13.53
Other Gand A
9.28
-3.97%
9.66
-14.90%
11.36
-16.05%
13.53
Total Expenses
12.10
-27.34%
16.65
-0.95%
16.81
-27.21%
23.09
Operating Income
-12.10
+27.34%
-16.65
+0.95%
-16.81
+27.21%
-23.09
Total Operating Income As Reported
-17.27
+20.18%
-21.64
-28.78%
-16.81
+27.21%
-23.09
EBITDA
-17.35
+11.17%
-19.53
-95.25%
-10.00
+56.66%
-23.08
Normalized EBITDA
-9.11
+45.21%
-16.63
+0.66%
-16.74
+41.31%
-28.52
Reconciled Depreciation
0.00
-100.00%
0.01
+250.00%
0.00
+0.00%
0.00
EBIT
-17.35
+11.23%
-19.55
-95.31%
-10.01
+56.65%
-23.09
Total Unusual Items
-8.24
-183.72%
-2.90
-143.13%
6.74
+23.90%
5.44
Total Unusual Items Excluding Goodwill
-8.24
-183.72%
-2.90
-143.13%
6.74
+23.90%
5.44
Special Income Charges
-8.34
-67.01%
-5.00
0.00
—
Other Special Charges
3.16
—
—
—
Impairment Of Capital Assets
5.18
0.00
—
—
Restructuring And Mergern Acquisition
0.00
-100.00%
5.00
0.00
—
Net Income
-17.30
+12.60%
-19.79
-97.75%
-10.01
+43.61%
-17.75
Pretax Income
-18.30
+7.53%
-19.79
-97.75%
-10.01
+43.61%
-17.75
Net Non Operating Interest Income Expense
-0.95
-301.69%
-0.24
-387.80%
0.08
+78.26%
0.05
Interest Expense Non Operating
0.95
+288.93%
0.24
0.00
—
Net Interest Income
-0.95
-301.69%
-0.24
-387.80%
0.08
+78.26%
0.05
Interest Expense
0.95
+288.93%
0.24
0.00
—
Interest Income Non Operating
0.00
-87.50%
0.01
-90.24%
0.08
+78.26%
0.05
Interest Income
0.00
-87.50%
0.01
-90.24%
0.08
+78.26%
0.05
Other Income Expense
-5.26
-80.81%
-2.91
-143.30%
6.72
+26.86%
5.29
Other Non Operating Income Expenses
2.98
+99566.67%
-0.00
+84.21%
-0.02
+86.62%
-0.14
Gain On Sale Of Security
0.10
-95.12%
2.09
-68.95%
6.74
+23.90%
5.44
Tax Provision
-1.00
0.00
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
-0.45
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-17.30
+12.60%
-19.79
-97.75%
-10.01
+43.61%
-17.75
Net Income From Continuing Operation Net Minority Interest
-17.30
+12.60%
-19.79
-97.75%
-10.01
+43.61%
-17.75
Net Income From Continuing And Discontinued Operation
-17.30
+12.60%
-19.79
-97.75%
-10.01
+43.61%
-17.75
Net Income Continuous Operations
-17.30
+12.60%
-19.79
-97.75%
-10.01
+43.61%
-17.75
Normalized Income
-9.51
+43.69%
-16.89
-0.85%
-16.74
+27.78%
-23.18
Net Income Common Stockholders
-17.30
+12.60%
-19.79
-97.75%
-10.01
+43.61%
-17.75
Diluted EPS
0.00
0.00
0.00
+100.00%
-216.00
Basic EPS
0.00
0.00
0.00
+100.00%
-216.00
Basic Average Shares
0.84
+181.85%
0.30
+144.03%
0.12
+56.79%
0.08
Diluted Average Shares
0.84
+181.85%
0.30
+144.03%
0.12
+56.79%
0.08
Diluted NI Availto Com Stockholders
-17.30
+12.60%
-19.79
-97.75%
-10.01
+43.61%
-17.75
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
47.89
-5.28%
50.56
+1061.01%
4.36
-68.52%
13.83
Current Assets
5.46
+85.03%
2.95
-32.00%
4.34
-68.58%
13.81
Cash Cash Equivalents And Short Term Investments
5.20
+100.19%
2.60
-32.41%
3.85
-70.98%
13.25
Cash And Cash Equivalents
5.20
+100.19%
2.60
-32.41%
3.85
-70.98%
13.25
Cash Financial
5.20
+100.19%
2.60
-32.41%
3.85
-70.98%
13.25
Prepaid Assets
0.18
+101.09%
0.09
-69.23%
0.30
-35.70%
0.47
Restricted Cash
0.06
+0.00%
0.06
0.00
—
Other Current Assets
0.01
-93.03%
0.20
+2.03%
0.20
+97.00%
0.10
Total Non Current Assets
42.43
-10.88%
47.61
+339971.43%
0.01
-17.65%
0.02
Net PPE
—
—
—
—
Gross PPE
—
—
—
—
Accumulated Depreciation
—
—
—
—
Machinery Furniture Equipment
—
—
—
—
Goodwill And Other Intangible Assets
42.43
-10.88%
47.61
+339971.43%
0.01
-17.65%
0.02
Goodwill
8.43
+0.00%
8.43
—
—
Other Intangible Assets
34.00
-13.22%
39.18
+279757.14%
0.01
-17.65%
0.02
Total Liabilities Net Minority Interest
19.56
-30.95%
28.33
+518.08%
4.58
-61.93%
12.04
Current Liabilities
12.35
-37.97%
19.91
+334.34%
4.58
-61.93%
12.04
Payables And Accrued Expenses
10.33
-31.44%
15.07
+394.13%
3.05
+14.28%
2.67
Payables
8.77
-29.31%
12.41
+642.49%
1.67
+76.45%
0.95
Accounts Payable
8.77
-29.31%
12.41
+642.49%
1.67
+76.45%
0.95
Current Accrued Expenses
1.56
-41.37%
2.66
+93.18%
1.38
-19.92%
1.72
Pensionand Other Post Retirement Benefit Plans Current
0.78
+64.90%
0.47
+152.94%
0.19
-86.89%
1.43
Current Debt And Capital Lease Obligation
0.75
-76.87%
3.26
—
—
Current Debt
0.75
-76.87%
3.26
—
—
Other Current Borrowings
0.67
-29.16%
0.95
—
—
Other Current Liabilities
0.48
-56.15%
1.11
-17.89%
1.35
-83.05%
7.95
Total Non Current Liabilities Net Minority Interest
7.21
-14.37%
8.42
0.00
0.00
Non Current Deferred Liabilities
6.95
-13.53%
8.04
0.00
—
Non Current Deferred Taxes Liabilities
6.95
-13.53%
8.04
0.00
—
Other Non Current Liabilities
0.03
-91.91%
0.38
—
—
Stockholders Equity
28.33
+27.44%
22.23
+9806.99%
-0.23
-112.79%
1.79
Common Stock Equity
28.33
+27.44%
22.23
+9806.99%
-0.23
-112.79%
1.79
Capital Stock
0.00
-100.00%
5.32
+301.74%
1.32
+77.72%
0.74
Common Stock
0.00
-100.00%
5.32
+301.74%
1.32
+77.72%
0.74
Share Issued
90,536.88
+70.22%
53,186.92
+301.89%
13,234.32
+77.76%
7,444.92
Ordinary Shares Number
90,536.88
+70.22%
53,186.92
+301.89%
13,234.32
+77.76%
7,444.92
Additional Paid In Capital
293.66
+10.86%
264.90
+16.72%
226.95
+3.50%
219.27
Retained Earnings
-264.55
-7.00%
-247.25
-8.70%
-227.46
-4.60%
-217.45
Gains Losses Not Affecting Retained Earnings
-0.78
-5.96%
-0.74
+29.04%
-1.04
-34.89%
-0.77
Other Equity Adjustments
-0.78
-5.96%
-0.74
+29.04%
-1.04
-34.89%
-0.77
Total Equity Gross Minority Interest
28.33
+27.44%
22.23
+9806.99%
-0.23
-112.79%
1.79
Total Capitalization
28.33
+27.44%
22.23
+9806.99%
-0.23
-112.79%
1.79
Working Capital
-6.89
+59.38%
-16.96
-6878.60%
-0.24
-113.70%
1.77
Invested Capital
29.08
+14.10%
25.49
+11230.57%
-0.23
-112.79%
1.79
Total Debt
0.75
-76.87%
3.26
—
—
Net Debt
—
0.66
—
—
Net Tangible Assets
-14.10
+44.44%
-25.38
-10344.86%
-0.24
-113.70%
1.77
Tangible Book Value
-14.10
+44.44%
-25.38
-10344.86%
-0.24
-113.70%
1.77
Current Notes Payable
0.08
-96.49%
2.31
0.00
—
Derivative Product Liabilities
0.23
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-10.57
+15.81%
-12.55
+23.61%
-16.43
+23.59%
-21.50
Cash Flow From Continuing Operating Activities
-10.57
+15.81%
-12.55
+23.61%
-16.43
+23.59%
-21.50
Net Income From Continuing Operations
-17.30
+12.60%
-19.79
-97.75%
-10.01
+43.61%
-17.75
Depreciation Amortization Depletion
0.00
-100.00%
0.01
+250.00%
0.00
+0.00%
0.00
Depreciation And Amortization
0.00
-100.00%
0.01
+250.00%
0.00
+0.00%
0.00
Other Non Cash Items
-2.37
-973.80%
0.27
+90.85%
0.14
—
Stock Based Compensation
2.89
+28.73%
2.25
+95.22%
1.15
+56.46%
0.73
Asset Impairment Charge
5.18
0.00
—
—
Deferred Tax
-1.09
0.00
—
—
Deferred Income Tax
-1.09
0.00
—
—
Operating Gains Losses
2.52
+237.70%
-1.83
+73.30%
-6.85
-28.91%
-5.32
Gain Loss On Investment Securities
-0.55
+73.86%
-2.08
+68.40%
-6.60
-32.43%
-4.98
Net Foreign Currency Exchange Gain Loss
-0.10
-138.82%
0.26
+200.00%
-0.26
+23.65%
-0.33
Change In Working Capital
-0.40
-106.18%
6.54
+855.08%
-0.87
-205.35%
0.82
Change In Prepaid Assets
0.59
-54.86%
1.32
+1780.00%
0.07
-95.88%
1.70
Change In Payables And Accrued Expense
-1.00
-119.11%
5.22
+658.01%
-0.94
-6.73%
-0.88
Investing Cash Flow
0.00
-100.00%
0.38
0.00
—
Cash Flow From Continuing Investing Activities
0.00
-100.00%
0.38
0.00
—
Net Business Purchase And Sale
0.00
-100.00%
0.38
0.00
—
Financing Cash Flow
13.17
+19.87%
10.99
+56.52%
7.02
-72.24%
25.29
Cash Flow From Continuing Financing Activities
13.17
+19.87%
10.99
+56.52%
7.02
-72.24%
25.29
Net Issuance Payments Of Debt
1.05
+222.46%
-0.85
0.00
—
Issuance Of Debt
2.10
+109.90%
1.00
0.00
—
Repayment Of Debt
-1.05
+43.29%
-1.85
0.00
—
Short Term Debt Issuance
2.10
+109.90%
1.00
0.00
—
Short Term Debt Payments
-1.05
+43.29%
-1.85
0.00
—
Net Short Term Debt Issuance
1.05
+222.46%
-0.85
0.00
—
Net Common Stock Issuance
10.72
-9.23%
11.81
+68.40%
7.02
-72.15%
25.19
Proceeds From Stock Option Exercised
1.40
+69850.00%
0.00
-50.00%
0.00
-95.74%
0.09
Net Other Financing Charges
—
0.03
—
—
Changes In Cash
2.60
+320.22%
-1.18
+87.44%
-9.41
-348.73%
3.78
Effect Of Exchange Rate Changes
0.00
+125.00%
-0.00
-157.14%
0.01
-93.33%
0.10
Beginning Cash Position
2.66
-30.85%
3.85
-70.98%
13.25
+41.54%
9.36
End Cash Position
5.26
+97.93%
2.66
-30.85%
3.85
-70.98%
13.25
Free Cash Flow
-10.57
+15.81%
-12.55
+23.61%
-16.43
+23.59%
-21.50
Interest Paid Supplemental Data
0.10
-29.37%
0.14
0.00
—
Income Tax Paid Supplemental Data
0.00
0.00
—
—
Common Stock Issuance
10.72
-9.23%
11.81
+68.40%
7.02
-72.15%
25.19
Issuance Of Capital Stock
10.72
-9.23%
11.81
+68.40%
7.02
-72.15%
25.19
Sale Of Business
0.00
-100.00%
0.38
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category